Recurrent Childhood Soft Tissue Sarcoma Completed Phase 2 Trials for Cixutumumab (DB12250)

IndicationStatusPhase
DBCOND0029296 (Recurrent Childhood Soft Tissue Sarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00831844Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsTreatment